|
Oct 1
|
Y-mAbs to Participate in Upcoming Investor Conferences in October
|
|
Sep 25
|
While shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) are in the black over 1 year, those who bought a week ago aren't so fortunate
|
|
Sep 3
|
Y-mAbs to Participate in Upcoming Investor Conferences in September
|
|
May 9
|
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Y-mAbs Therapeutics Inc (YMAB) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
|
|
May 9
|
Q1 2024 Y-mAbs Therapeutics Inc Earnings Call
|
|
May 7
|
Y-mAbs Therapeutics Reports Q1 2024 Results: Aligns with EPS Projections, Misses Revenue Estimates
|
|
May 7
|
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 7
|
Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments
|
|
Apr 26
|
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
|
|
Apr 25
|
Y-mAbs to Present at 2024 ASCO Annual Meeting
|
|
Apr 18
|
Y-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161%
|
|
Mar 28
|
Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet
|
|
Mar 20
|
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
|
|
Mar 14
|
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
|
|
Mar 12
|
Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?
|
|
Mar 5
|
Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice
|
|
Mar 4
|
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcript
|
|
Mar 4
|
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
|
|
Feb 16
|
CRISPR Therapeutics AG (CRSP) Moves 6.9% Higher: Will This Strength Last?
|